BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Scientific Program
 
BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Theme: Rethinking the Next Big Things in Pharma Innovations
Time: August 16-19, 2018 
Place: Boston Marriott Cambridge, USA
 
Scientific Program
Stream 1 Stream 2 Stream 3 Stream 4 Stream 5

 

Stream 2: Drug Discovery X-Hubs
-New Vision on Drug Discovery Science and Technology

Substream 2-1: Dynamic Bio X-Hub
Substream 2-2: Enabled Technologies for Drug Discovery
Substream 2-3: Computer-aided Drug Discovery

 

Substream 2-1: Dynamic Bio X-Hub
 

Session 2101: Decoding Mechanism of Diseases and Drug Discovery

Day 1: Afternoon, Thursday, August 16, 2018

Place: Discovery Room, 3rd Floor

13:30-17:30

Chair: Dr. Jack Rogers,  Director, Neurochemistry Laboratory, Massachusetts General Hospital, USA
Co-Chair: Dr. Yaakov Naparstek, Professor of Medicine, Hadassah University Hospital, Israel
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55

Title: Cooperative RNA Modulation to Improve Iron Homeostasis Specific to Neurons While Providing Anti-amyloid Efficacy as a Potential Alzheimer’s Disease Therapy

Dr. Jack Rogers, Director, Neurochemistry Laboratory, Massachusetts General Hospital, USA

13:55-14:15 Title: The Use of Isotopic Ratio Outlier Analysis for Metabolomic Target Discovery in Model Organisms
Dr. Irwin Kurland, Associate Professor & Director, Albert Einstein College of Medicine, USA
14:15-14:35 Title: Chatting with a Neuron
Dr. Frank Elsen, Electrophysiology Application Scientist, Harvard Bioscience, USA
14:35-14:55

Title: Berberine Protects Cytokine Induced Inflammation through Multiple Pathways

Dr. Lixin Li, Associate Professor, Central Michigan University, USA

14:55-15:15

Title: Novel Combinational Therapy for Multiple Food Allergic Patients

Dr. R. Sharon Chinthrajah, Medical Director, Clinical Translational Research Unit, Sean N. Parker Center for Allergy & Asthma Research, Stanford University, USA

15:15-15:30 Coffee Break
15:30-15:50 Title: Protective Antibodies Against HSP60 for Autoimmune Inflammatory Diseases
Dr. Yaakov Naparstek, Professor of Medicine, Hadassah University Hospital, Israel
15:50-16:10 Title: The Development and Application of New PET Neuroimaging Probes
Dr. Changning Wang, Assistant Professor of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, USA
16:10-16:30

Title: Molecular Mechanisms Underlying Vitamin D Deficiency-induced Hypertension

Dr. Songcang Chen, Senior Scientist, University of California, San Francisco, USA
16:30-16:50 Title: Cancer-derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor
Dr. Cheng-Chin Kuo, Associate Investigator, Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan
16:50-17:10

Title: A Non-tight Junction Function of Claudin-7 in Lung Cancer Cell Progression

Dr. Do Hyung Kim, Postdoctoral Fellow, Johns Hopkins School of Medicine, USA

 

17:10-17:30

Title: Newly Elicited Pluripotent Stem Cells (nEPS)

Ms. Mindy Min Sun Oh, CEO, bBHC Stem Cell Treatment & Research Institute, South Korea

 

Session 2102: Toxicology and Drug Discovery

Day 1: Afternoon, Thursday, August 16, 2018

Place: Endeavor Room, 3rd Floor

13:30-15:15

Chair: Dr. Tamara Fridman, CEO, Vanasyl LLC., USA
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55 Title: The Crucial Role Process Equipment Plays in the Shift from Drug Discovery to Mass Drug Production; Ensuring Production is Successful
Dr. Tamara Fridman, CEO and Engineer, Vanasyl LLC., USA
13:55-14:15

Title: Antifungal Activity, Lipophilicity, Phyto and Cytotoxicity of Homo and Heteroleptic Complexes of Ag(I) with Sulfonamides and Albendazole

Dr. Marcela Rizzotto, Chair, Department of Chemistry-Physics, Facultad de Bioquímica y Farmacia, Universidad Nacional de Rosario, Argentina

14:15-14:35 Title: Kidney Organoids for Nephrotoxicity Testing and Drug Discovery

Dr. Ryuji Morizane, Assistant Professor, Harvard Medical School; Associate Biologist, Renal Division, Brigham and Women’s Hospital; Affiliated Faculty, Harvard Stem Cell Institute, USA

14:35-14:55 Title: Genetic Polymorphism and Prediction of Drug Toxicity from Protein Structures
Dr. Kyonghee Son, Visiting Scientist, University of Massachusetts Medical School, USA
14:55-15:15

Title: Predictive Toxicology Tools and Applications in Drug Discovery – Mutagenicity Assessment of Pharmaceutical Impurities and Estimation of Skin Sensitization Potency

Dr. Joel Cohen, Senior Toxicologist, Gradient, USA
15:15-15:30 Coffee Break

  

Session 2103: Microbiology and Drug Discovery

Day 2: Morning, Friday, August 17, 2018

Place: Enterprise Room, 3rd Floor

08:30-09:50

Chair: Dr. Claudia Gallert, Full Professor, University of Applied Science Emden Leer, Germany
Time FaceOn Speeches and Speakers
08:30-08:35 Chair's Introduction
08:35-09:00 Title: Staphylococci from Aquatic Environments with Inducible Resistance to Macrolides, Lincosamides and Streptogramin B (MLSB) - Induction of Cross-resistance against MLSB by the Omnipresent Metabolite Anhydroerythromycin
Dr. Claudia Gallert, Full Professor, University of Applied Science Emden Leer, Germany
09:00-09:25 Title: Learning from Ecology. Controlling  Pathogens as Nature Does: By Their Self-DNA
Dr. Stefano Mazzoleni, Full Professor,Applied Ecology and Modelling, University of Napoli “Federico II”, Italy
09:25-09:50 Title: Immunization against Newcastle Disease and Bird Flu H5N1 CDC Strain Using Cinnamon Fraction
Dr. Michael Ovadia, Professor Emeritus, Department of Zoology, Tel-Aviv University, Israel
09:50-10:05 Coffee Break

   

Session 2104: Oncology and Drug Discovery

Day 3: Morning, Saturday, August 18, 2018

Place: Discovery Room, 3rd Floor

08:30-12:10

Chair: Dr. Michael R. Briggs, Woodland Pharmaceuticals LLC; Tufts Cummings School of Veterinary Medicine, USA
Co-Chair: Dr. Ping Xie, Associate Professor, Rutgers University, USA
Time FaceOn Speeches and Speakers
08:30-08:35 Chair's Introduction
08:35-08:55 Keynote Speech
Title: Cancer Stem Cells: Challenges and Opportunities for Drug Discovery
Dr. Bakhos A. Tannous, Associate Professor of Neurology and Director, Harvard Medical School and Massachusetts General Hospital, USA
08:55-09:15

Title: Metabolic Disease Drivers of Hepatocellular Carcinoma, A New Disease Paradigm

Dr. Michael R. Briggs, Woodland Pharmaceuticals LLC; Tufts Cummings School of Veterinary Medicine, USA

09:15-09:35 Title: Comparison between HER2 Expression in Primary Breast Cancer before and after Neoadjuvant Therapy
Dr. Jamal Zidan,  Head, Oncology Division, Ziv Medical Center, Faculty of Medicine, Bar-Ilan University, Israel
09:35-09:55 Title: Perioperative Use of NSAID Might Prevent Early Relapses in Breast and Other Cancers: An Upstream Approach
Dr. Michael Retsky, Research Associate,Harvard TH Chan School of Public Health, USA; Honorary Reader, University College London, UK
09:55-10:15

Title: Targeting the Epigenome in High Grade Ovarian Cancer

Dr. Daniela Dinulescu, Assistant Professor, Harvard Medical School, USA

10:15-10:30 Coffee Break
10:30-10:50

Title: TRAF3 Specifically Targets the Phosphocholine-phosphatidylcholine-phosphatidylethanolamine Metabolic Pathway in B Lymphocytes

Dr. Ping Xie, Associate Professor, Rutgers University, USA
10:50-11:10 Title: Lonidamine Induced Selective Acidification and De-energization Enhances Tumor Response to Chemo and Radiation Therapy
Dr. Kavindra Nath, Research Assistant Professor, University of Pennsylvania, USA
11:10-11:30 Title: A Big Data Analysis Unveils the Gene Interactions in Cancer for Drug Development
Dr. Benjamin Yat Ming Yung, Chair Professor of Biomedical Science, Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China
11:30-11:50

Title: An ‘out of the box’ Approach towards Eliminating Mammary Epithelial Carcinoma from Its Root

Dr. Tanya Das, Senior Professor, Division of Molecular Medicine; Dean, Research and Development, Bose Institute, India

11:50-12:10

 

Title: Immune-rejuvenation Therapy of Cancer

Dr. Gaurisankar Sa, Senior Professor & Chairman of Molecular Medicine, Bose Institute, India

  

Session 2105: Molecular Biomedicine in Drug Discovery

Day 3: Afternoon, Saturday, August 18, 2018

Place: Endeavor Room, 3rd Floor

13:30-15:15

Chair: Dr. Johnathan R. Whetstine, Associate Professor of Medicine, Harvard Medical School and Massachusetts General Hospital Cancer Center, USA
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55

Title: Small Molecular Inhibitors for Prostate Cancer and Bacterial Biofilms

Dr. Hai-Feng Ji, Professor, Department of Chemistry, Drexel University, USA

13:55-14:15 Title: Epigenetics is a Gatekeeper to DNA Amplification
Dr. Johnathan R. Whetstine, Associate Professor of Medicine, Harvard Medical School and Massachusetts General Hospital Cancer Center, USA
14:15-14:35 Title: Exploring Applications of Thio-phosphate in Drug Development
Dr. Elizabeth G. Frayne, Associate Faculty Member, University of Phoenix, USA
14:35-14:55

Title: Exploring the Ligand Recognition Properties of the Human Vasopressin Receptors by Using Molecular Modeling and Molecular Dynamics Simulations

Dr. Marlet T. Martinez Archundia, Researcher, Superior School of Medicine, National Polytechnic Institute (IPN), Mexico

14:55-15:15

Title: Using Mesenchymal Stem Cells as a Platform for ZFN Mediated Artificial Gene Knock-in

Dr. Krissanapong Manotham, Advisor, SS Manufacturing Co.,Ltd; Lerdsin General Hospital, Thailand

15:15-15:30 Coffee Break

   

Substream 2-2: Enabled Technologies for Drug Discovery
 

Session 2201: Novel Analytical Technology for Drug Discovery

Day 1: Afternoon, Thursday, August 16, 2018

Place: Enterprise Room, 3rd Floor

13:30-17:10

Chair: Dr. Kerstin Walke, Head of Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Co-Chair: Dr. Robert G. Lowery, President & CEO, BellBrook Labs, USA

Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55 Title: World's First Fully (Hybrid) Integrated and Waferscale Manufacturable Photonic Interferometric Biosensor-array Chip-module with Unparalleled Sensitivity and Reproducibility, Applicable in Both Drug Screening/Optimization and Companion Diagnostics
Dr. Henk Leeuwis, Senior Vice President, Strategy and Innovation, LioniX International BV,  The Netherlands
13:55-14:15 Title: Formulation of NBE: The Polysorbat Discussion Current Overview Relates Issues Degradation Pathways and Potential Solutions Challenges in Analytics
Dr. Kerstin Walke, Head of Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
14:15-14:35  

Title: Advances in Capillary Zone Electrophoresis for Charge Heterogeneity Testing of Monoclonal Antibodies

Dr. Mark Lies, Senior Manager, CE & BioPharma, SCIEX, USA

14:35-14:55 Title: Advances in NGS Library Prep QC : Automated Pulsed-field Capillary Electrophoresis with Femtogram Level Detection
Dr. Kit-Sum Wong, Director, Advanced Analytical Technologies Inc., USA
14:55-15:15
 

Title: Solutions for Automation of GMP Assays by Catalent Biologics

Mr. Christopher Hepler, Group Leader, Biologics Analytical Services, Catalent Biologicss, USA

15:15-15:30 Coffee Break
15:30-15:50 Title: Appliction of Multiple Configurations of a Photonic Based Microscale Calorimeter in the Drug Discovery Process

Dr. Gregory Kowalski, Associate Professor, Department of Mechanical and Industrial Engineering, Northeastern University, USA

15:50-16:10

Title:  Measuring Drug Residence Times in an HTS Format with the Transcreener® ADP2 Kinase Assay

Dr. Robert G. Lowery, President & CEO, BellBrook Labs, USA

16:10-16:30

Title: Drugging the Undruggable: Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Inhibitor of Cadherin Homophilic Interaction

Dr. Emilio Parisini, Group Leader, Istituto Italiano di Tecnologia, Italy

16:30-16:50

Title: Microfluidic Impedance Cytometry for Prediction of Patient Response to Targeted Cancer Therapy: A Data-driven Approach

Dr. Mehdi Javanmard, Assistant Professor,  Rutgers University, USA

16:50-17:10 Title: Following Fluorinated Drugs by Molecular Absorption Spectrometry – From Cancer Cells to Body Fluids
Mr. Carlos Abad Andrade, Research Associate, Federal Institute for Materials Research and Testing -BAM, Germany
 18:00-20:00 Welcome Banquet & Art Performance 

    

 

Session 2202: Other Enabled Technologies for Drug Discovery

Day 2: Afternoon, Friday, August 17, 2018

Place: Discovery Room, 3rd Floor

13:30-17:10

Chair: Dr. Chengcang C. Wu, CEO & Founder, Intact Genomics, Inc., USA
Co-Chair: Mr. Lekhram Changoer, CTO/Director, AXIM Biotechnologies, USA/The Netherlands
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55

 

Title: Chemical Biology Approach for Biologics Drug Discovery and the Identification of Antibody-drug Conjugate T-CE-040
Dr. Jason Shaoyun Xiang, Founder, Hangzhou Polymed, China

 

13:55-14:15 Title: Retrosynthetic Software for Practicing Chemists: Novel and Efficient in Silico Pathway Design Validated at the Bench
Dr. Lindsey Hess Rickershauser, Technical Application Scientist, Cheminformatics Technologies, MilliporeSigma (a Business of Merck KGaA, Germany), USA
14:15-14:35 Title: Revive Large-scale Natural Product and Drug Discovery from Microbes and Soil Metagenomes
Dr. Chengcang C. Wu, CEO & Founder, Intact Genomics, Inc., USA
14:35-14:55 Title: Novel Natural Product-based Macrocyclic Platform: MacroEvoLution
Dr. Dietmar Wolf, Executive Vice President, AnalytiCon Discovery, LCC, Germany
14:55-15:15   Title: Metabolic Detection of Bruton’s Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
Dr. Seung-Cheol Lee, Research Assistant Professor,Department of Radiology, University of Pennsylvania, USA
15:15-15:30 Coffee Break
15:30-15:50

 

Title: Novel cGMP Technologies for Extraction, Purification and Conversion of Cannabinoids for the Pharmaceutical Industry

Mr. Lekhram Changoer, CTO/Director, AXIM Biotechnologies, USA/The Netherlands

 

15:50-16:10 Title: Heterogeneous Catalysis for Drug Synthesis
Dr. Antonio Leyva-Perez, Distinguished Researcher, Universidad Politécnica de Valencia-Consejo Superior de Investigaciones Científicas, Spain
16:10-16:30 Title: Organolithium Chemistry Using Flow Microreactors
Dr. Aiichiro Nagaki, Associate Professor, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Japan
16:30-16:50

Title: Hollow Fiber Model - in vivo Screening in Cancer Drug Discovery

Dr. Bettina Stahnke, Business Development Manager, ProQinase GmbH, Germany
16:50-17:10

Title: Responsive Molecular Imaging Biosensors for Precise Therapeutic Solutions in Regenerative Medicine

Dr. Ethel J. Ngen, Research Faculty, Johns Hopkins University School of Medicine, USA

 

 

Substream 2-3: Computer-aided Drug Discovery
 

Session 2301: Computer-aided Drug Discovery

Day 2: Afternoon, Friday, August 17, 2018

Place: Endeavor Room, 3rd Floor

13:30-17:10

Chair: Dr. Zhenhong Li, Senior Principal Scientist, Medicine Design Modeling and Simulation, Pfizer Global Research and Development, USA

Co-Chair: Dr. Pavel Pospisil, PMI R&D, Philip Morris Products S.A., Switzerland

Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-14:00

 

Title: Translational ADME and PBPK/PD Sciences to Impact Drug Discovery and Development
Dr. Tycho H. Heimbach, Director, Novartis Institutes for Biomedical Research, USA


14:00-14:25

Title: Big Data Driven Drug Development Strategy for Alzheimer Disease

Dr. Gyungah Jun, Assistant Professor, Boston University School of Medicine, USA


14:25-14:50 Title: A Model-based Assessment of Plasma Citrate Flux into the Liver: Implications for NaCT as a Therapeutic Target
Dr. Zhenhong Li, Senior Principal Scientist, Medicine Design Modeling and Simulation, Pfizer Global Research and Development, USA
14:50-15:15 Title: Using DILIsym, A Quantitative Systems Toxicology Modeling Tool of Drug-induced Liver Injury (DILI), to Assess DILI Risk in Drug Development
Dr. Brett A. Howell, President, DILIsym Services Inc., a Simulations Plus Company; Associate Director, DILI-sim Initiative, USA
15:15-15:30 Coffee Break
15:30-15:55 Title: Integrated Informatics Platform for Drug R&D
Dr. Jinbo Lee, Chief Scientific Officer, Scilligence Corporation, USA
15:55-16:20

Title: Software Tool for Population Pharmacokinetic Analysis and Model Preparation with Usage of Iterative Two-Stage Bayesian Technique

Dr. Jiří Douša, Head of Medical Softtware Development Team, Mediware Company, Czech Republic
16:20-16:45

Title: Building an Efficient R & D Chemo-centric Data Repository System that Leads to Knowledge Discovery

Dr. Pavel Pospisil, PMI R&D, Philip Morris Products S.A., Switzerland

16:45-17:10

Title: Discovery and Development of Novel Inhibitors of the MDMs Proteins for Cancer Therapy

Dr. Valeria La Pietra, Assistant Professor, University of Naples "Federico II", Italy

 

© 2003-2018 All rights reserved by BIT Congress Inc.
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897